Naiyer Rizvi is Chief Medical Officer at Synthekine. OpenAlex indexes 481 publications with 65,566 citations (h-index 82); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Naiyer Rizvi as a Highly Cited Researcher (Clinical Medicine, 2021-2024).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Naiyer Rizvi, MD, is Chief Medical Officer at Synthekine. The public record shows 481 publications with 65,566 citations (h-index 82), centered on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 7 companies, 3 NIH-funded awards (2005–2021).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 224.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Sponsor: Canadian Cancer Trials Group
- Genetic Predictors of Benefit to Pembrolizumab
Sponsor: Columbia University
Industry payments
Updated 27 Aug 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
- Regeneron Pharmaceuticals, Inc.Program year20212 payments
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2005–2021 per NIH RePORTER. The latest:
- Elucidating genetics of response to immune checkpoint blockade in lung cancer
Columbia University Health Sciences
FY2021$203,550R01CA205426 - Elucidating genetics of response to immune checkpoint blockade in lung cancer
Columbia University Health Sciences
FY2020$558,644R01CA205426 - Elucidating genetics of response to immune checkpoint blockade in lung cancer
Columbia University Health Sciences
FY2019$541,884R01CA205426
Congress activity
Updated 27 Aug 2026
122 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.
Clinical cancer research
Clinical Trial2026 - Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy.
Cancer immunology research
Article2023 - First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Journal for immunotherapy of cancer
Clinical Trial2022
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer6,238 citations2015
- 04
- 05Nivolumab plus Ipilimumab in Advanced Melanoma4,221 citations2013
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/naiyer-rizvi-md-1
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/naiyer-rizvi-a6562b200
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Naiyer-A-Rizvi-38609205
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/synthekine_next-week-our-chief-medical-officer-naiyer-activity-7060283393799852032-K5fT
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile listing him as Chief Medical Officer at Synthekine, New York, NY
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship in Hematology and Medical Oncology
Beth Israel Deaconess Medical Center/Harvard Medical School
1995verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- Residency
University of Manitoba Affiliated Hospitals
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →synthekine.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Secondary affiliations
appointments beyond the home institution- Columbia University Irving Medical Center
Price Family Professor of Medicine, Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy (past role, prior to Synthekine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →synthekine.com ↗ - NewYork-Presbyterian Hospital / Herbert Irving Pavilion
Research Director, Price Family Comprehensive Center for Chest Care (past role)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctors.nyp.org ↗ - Co-founder and Scientific Advisory Board / Board of Directors member
Gritstone bio (formerly Gritstone Oncology)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →synthekine.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →join.targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center